Sign In
Buy FENC
Fennec Pharmaceuticals Earnings Calls
| Release date | May 14, 2026 |
| EPS estimate | -$0.0200 |
| EPS actual | $0.0100 |
| EPS Surprise | 150.00% |
| Revenue estimate | 13.899M |
| Revenue actual | 15.1M |
| Revenue Surprise | 8.64% |
| Release date | Mar 24, 2026 |
| EPS estimate | $0.0300 |
| EPS actual | -$0.110 |
| EPS Surprise | -466.67% |
| Revenue estimate | 14.733M |
| Revenue actual | 13.777M |
| Revenue Surprise | -6.49% |
| Release date | Nov 13, 2025 |
| EPS estimate | -$0.0800 |
| EPS actual | -$0.0200 |
| EPS Surprise | 75.00% |
| Revenue estimate | 14.689M |
| Revenue actual | 12.462M |
| Revenue Surprise | -15.16% |
| Release date | Aug 14, 2025 |
| EPS estimate | -$0.0600 |
| EPS actual | -$0.110 |
| EPS Surprise | -83.33% |
| Revenue estimate | 9.562M |
| Revenue actual | 9.652M |
| Revenue Surprise | 0.94% |
Last 4 Quarters for Fennec Pharmaceuticals
Below you can see how FENC performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 14, 2025 |
| Price on release | $8.53 |
| EPS estimate | -$0.0600 |
| EPS actual | -$0.110 |
| EPS surprise | -83.33% |
| Date | Price |
|---|---|
| Aug 08, 2025 | $8.33 |
| Aug 11, 2025 | $8.25 |
| Aug 12, 2025 | $9.24 |
| Aug 13, 2025 | $9.11 |
| Aug 14, 2025 | $8.53 |
| Aug 15, 2025 | $8.36 |
| Aug 18, 2025 | $8.20 |
| Aug 19, 2025 | $7.91 |
| Aug 20, 2025 | $8.08 |
| 4 days before | 2.40% |
| 4 days after | -5.28% |
| On release day | -1.99% |
| Change in period | -3.00% |
| Release date | Nov 13, 2025 |
| Price on release | $7.69 |
| EPS estimate | -$0.0800 |
| EPS actual | -$0.0200 |
| EPS surprise | 75.00% |
| Date | Price |
|---|---|
| Nov 07, 2025 | $7.98 |
| Nov 10, 2025 | $7.68 |
| Nov 11, 2025 | $7.92 |
| Nov 12, 2025 | $7.78 |
| Nov 13, 2025 | $7.69 |
| Nov 14, 2025 | $7.86 |
| Nov 17, 2025 | $8.75 |
| Nov 18, 2025 | $8.75 |
| Nov 19, 2025 | $8.18 |
| 4 days before | -3.63% |
| 4 days after | 6.37% |
| On release day | 2.21% |
| Change in period | 2.51% |
| Release date | Mar 24, 2026 |
| Price on release | $6.02 |
| EPS estimate | $0.0300 |
| EPS actual | -$0.110 |
| EPS surprise | -466.67% |
| Date | Price |
|---|---|
| Mar 18, 2026 | $7.47 |
| Mar 19, 2026 | $7.65 |
| Mar 20, 2026 | $7.32 |
| Mar 23, 2026 | $7.45 |
| Mar 24, 2026 | $6.02 |
| Mar 25, 2026 | $6.17 |
| Mar 26, 2026 | $6.51 |
| Mar 27, 2026 | $5.91 |
| Mar 30, 2026 | $5.77 |
| 4 days before | -19.41% |
| 4 days after | -4.15% |
| On release day | 2.49% |
| Change in period | -22.76% |
| Release date | May 14, 2026 |
| Price on release | $9.24 |
| EPS estimate | -$0.0200 |
| EPS actual | $0.0100 |
| EPS surprise | 150.00% |
| Date | Price |
|---|---|
| May 08, 2026 | $6.93 |
| May 11, 2026 | $7.10 |
| May 12, 2026 | $7.03 |
| May 13, 2026 | $6.77 |
| May 14, 2026 | $9.24 |
| May 15, 2026 | $9.75 |
| May 18, 2026 | $9.60 |
| May 19, 2026 | $9.76 |
| May 20, 2026 | $9.75 |
| 4 days before | 33.33% |
| 4 days after | 5.52% |
| On release day | 5.52% |
| Change in period | 40.69% |
Fennec Pharmaceuticals Earnings Call Transcript Summary of Q1 2026
Fennec reported strong Q1 2026 momentum driven by commercial execution, expanded field coverage and growth in demand for PEDMARK. Net product sales were $15.1M (up ~73% YoY) — the sixth consecutive quarter of sales growth under the new commercial leadership — and April was the highest-demand month to date. The company expanded its commercial footprint via Project Ignite (14 new territories and 4 frontline managers), increased prescriber targeting from ~1,300 to >5,000, and saw Fennec HEARS hub performance improve (48% QoQ increase in completed infusions, conversion and adherence approaching 80%, and ~50% of April demand flowing through HEARS). Clinical momentum includes multiple investigator-initiated trials (ISTs) in AYA and adult populations and ASCO abstracts, supporting potential label expansion / broader adoption. Japan discussions and Norgine partnership progress were noted; however, a German milestone payment is not expected. OpEx (ex-stock comp) was ~$14M for the quarter, cash & equivalents were $40.1M as of 3/31/2026, the company generated positive operating cash flow in Q1, expects ~$50M cash OpEx in 2026 (front-loaded >60% in H1), and believes existing cash plus projected PEDMARK revenues are sufficient to fund the business under the current plan. Management emphasized continued focus on cross-functional execution, market-access initiatives (GPO relationships, order sets/EMR integration), and potential for future product or label expansion as commercial traction builds.
